BidaskClub upgraded shares of ZIOPHARM Oncology (NASDAQ:ZIOP) from a strong sell rating to a sell rating in a research note released on Thursday.
ZIOP has been the subject of a number of other research reports. Zacks Investment Research upgraded ZIOPHARM Oncology from a hold rating to a buy rating and set a $5.25 price target for the company in a report on Friday, November 10th. HC Wainwright restated a buy rating and issued a $9.50 price target on shares of ZIOPHARM Oncology in a report on Tuesday, November 7th. Raymond James Financial restated a hold rating on shares of ZIOPHARM Oncology in a report on Monday, December 11th. Finally, ValuEngine cut ZIOPHARM Oncology from a hold rating to a sell rating in a report on Friday, September 15th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of Hold and an average price target of $12.67.
ZIOPHARM Oncology (ZIOP) opened at $4.38 on Thursday. The firm has a market capitalization of $621.80, a P/E ratio of -8.42 and a beta of 1.44. ZIOPHARM Oncology has a fifty-two week low of $3.90 and a fifty-two week high of $7.88.
ZIOPHARM Oncology (NASDAQ:ZIOP) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.13). The company had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $1.66 million. The firm’s revenue was up .0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.11) EPS. analysts forecast that ZIOPHARM Oncology will post -0.54 earnings per share for the current year.
In other ZIOPHARM Oncology news, CEO Laurence James Neil Cooper bought 6,440 shares of ZIOPHARM Oncology stock in a transaction dated Wednesday, November 8th. The stock was bought at an average cost of $4.68 per share, for a total transaction of $30,139.20. Following the purchase, the chief executive officer now owns 1,083,731 shares in the company, valued at approximately $5,071,861.08. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 10.40% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of ZIOPHARM Oncology by 7.6% during the 2nd quarter. Vanguard Group Inc. now owns 7,864,470 shares of the biotechnology company’s stock valued at $48,917,000 after buying an additional 553,933 shares during the last quarter. State Street Corp boosted its stake in shares of ZIOPHARM Oncology by 12.8% during the 2nd quarter. State Street Corp now owns 4,556,264 shares of the biotechnology company’s stock valued at $28,342,000 after buying an additional 517,057 shares during the last quarter. Northern Trust Corp boosted its stake in shares of ZIOPHARM Oncology by 10.1% during the 2nd quarter. Northern Trust Corp now owns 1,630,858 shares of the biotechnology company’s stock valued at $10,144,000 after buying an additional 149,067 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its stake in ZIOPHARM Oncology by 6.6% during the third quarter. Schwab Charles Investment Management Inc. now owns 618,589 shares of the biotechnology company’s stock worth $3,799,000 after purchasing an additional 38,440 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in ZIOPHARM Oncology by 2.2% during the second quarter. Bank of New York Mellon Corp now owns 611,533 shares of the biotechnology company’s stock worth $3,804,000 after purchasing an additional 13,127 shares during the last quarter. Institutional investors own 40.23% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “ZIOPHARM Oncology (ZIOP) Upgraded to Sell at BidaskClub” was first posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://transcriptdaily.com/2018/01/08/ziopharm-oncology-ziop-upgraded-to-sell-at-bidaskclub.html.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.